Hepatoprotective effect of Antrodia Cinnamomea mycelia extract in subhealth Japanese adults: a randomized, double-blind, placebo-controlled clinical study.

Antrodia cinnamomea, a unique Taiwanese fungus (mushroom), has demonstrated the hepatoprotective activities in animals with liver injury. Nevertheless, there are few studies reporting the efficacy of the fungus in subhealth subjects (alanine aminotransferase (ALT) levels between 31 and 50 U/L and aspartate aminotransferase (AST) levels ≤ 50 U/L). In this study, we assessed the ameliorating effect of a A. cinnamomea mycelia extract (ACME) on liver health in asymptomatic individuals with marginally high ALT levels. Forty-four eligible Japanese adults were enrolled in this randomized, double-blind, placebo-controlled clinical study and instructed to take an ACME capsule (250 mg of ACME powder) or a placebo capsule daily for 12 weeks. The primary outcomes (i.e. ALT and AST) were analyzed at 0, 4, 8, and 12 weeks. No treatment-related adverse effects were observed throughout this study. In efficacy analyses with the per-protocol (PP) cohort of participants, there were no significant changes in ALT and AST levels within and between groups. However, subgroup analysis showed that ACME could significantly improve the mean ALT level of regular drinkers, consuming alcoholic drinks more than twice a week, after the study in comparison with the result of the placebo group. This exploratory study indicated that the ACME might effectively improve liver health in regular drinkers.

Evaluation of acute and sub-chronic toxicity of bitter melon seed extract in Wistar rats.

Pharmacological studies have revealed the potential antidiabetic effects of bitter melon seeds (Momordica charantia) in animals and humans. However, the sub-chronic safety of bitter melon seeds remains elusive. This exploratory study aimed to assess the acute and sub-chronic toxicity of a bitter melon seed extract from supercritical carbon dioxide (scCO2) extraction in Wistar rats based on the Organization for Economic Co-operation and Development (OECD) guidelines No. 423 and 408. No mortality and toxicity were observed in rats treated with a single dose of the extract during the 14-day observation period. The median lethal dose (LD50) of the extract was considered greater than 2000 mg/kg body weight (BW). For the sub-chronic toxicity study, male and female rats were orally administered daily doses of 0, 250, 500, and 1000 mg/kg BW for 90 days. No mortality, morbidity, and abnormal pathological and biochemical alterations were observed. The no-observed-adverse-effect-level (NOAEL) of the bitter melon seed extract was greater than 1000 mg/kg BW. Accordingly, bitter melon seed extract from scCO2 extraction may be considered a non-toxic dietary ingredient.

Ameliorating Effect of Crassocephalum rabens (Asteraceae) Extract on Skin Aging: A Randomized, Parallel, Double-Blind, and Placebo-Controlled Study.

Crassocephalum rabens (Asteraceae) is a common herb used in Taiwanese folk medicine to treat inflammation-related syndromes. Pharmacological studies have revealed that galactolipids exhibit anti-oxidative, anti-inflammatory, and anti-hyaluronidase activities and improve skin wrinkles, moisture, and elasticity in healthy subjects. However, the anti-aging effects of C. rabens and its primary active compound, 1,2-di-O-linolenoyl-3-O-ß-galactopyranosyl-sn-glycerol (dLGG), remain elusive. Here, we investigated whether C. rabens can improve skin conditions in healthy individuals using a double-blind approach. Forty enrolled volunteers were randomly and equally assigned to the control or treatment group and were required to take either a placebo or a C. rabens extract capsule daily for one month. Skin parameters were measured before and after the study. The results showed significant differences in skin elasticity, wrinkles, collagen content, brightness, and hydration between the baseline and week 4 in the treatment group. Particularly, compared with those in the placebo group, skin wrinkles (p < 0.05), brightness (p < 0.001), collagen content (p < 0.01), and UV spots (p < 0.05) were notably improved after treatment with the C. rabens extract. Our study successfully demonstrated the application of C. rabens in preventing skin aging. Further investigations will be conducted to study the underlying anti-aging mechanism of dLGG.

Corrigendum to "Assessment of the acute and sub-acute toxicity of the ethanolic extract of the aerial parts of Crassocephalum rabens (Asteraceae) in rats" [Toxicol. Rep. 9 (2022) 58-63].

[This corrects the article DOI: 10.1016/j.toxrep.2021.12.005.].

Assessment of the acute and sub-acute toxicity of the ethanolic extract of the aerial parts of Crassocephalum rabens (Asteraceae) in rats.

This pioneering study was to assess the acute and sub-acute toxicity of the ethanolic extract of the aerial parts of Crassocephalum rabens (Asteraceae) in rats. C. rabens is a common vegetable and herb for treating inflammation-related syndromes in Taiwan. Pharmacological studies have unveiled that the extracts of C. rabens have potential to become hepatoprotective, anti-inflammatory, or anti-cancer agents. The toxicological effects of the aerial parts of C. rabens in rodents are still elusive. For the acute toxicity study, rats were administrated with a single dose of 5,000 mg/kg body weight (BW) and observed for 14 days in accordance with the Organization for Economic Cooperation and Development (OECD) guideline No. 420. For the sub-acute toxicity study, animals were orally treated with daily doses of 0, 416.7, 833.3, and 1,666.7 mg/kg BW for 28 days based on the OECD guideline No. 407. The toxicity of the repeated dose was observed with anthropometric, hematological, and biochemical parameters as well as histology. The mortality and critical pathological and biochemical abnormalities were not observed in the acute and/or sub-acute toxicity studies. The oral median lethal dose (LD50) of the extract was greater than 5000 mg/kg BW. The no-observed-adverse-effect-level (NOAEL) in male and female rats was greater than 1,666.7 mg/kg BW. As such, the extract of the aerial parts of C. rabens is considered a non-toxic substance.

Exploring the Factors Affecting Bitter Melon Peptide Intake Behavior: A Health Belief Model Perspective.

PURPOSE: Diabetes mellitus (DM) patients need to control their blood sugar level in order to achieve a good quality of life. This study was conducted using the health belief model (HBM), to explore the factors behind the bitter melon peptide (BMP) intake behavior and the role of self-efficacy in the model. MATERIALS AND METHODS: The subjects were type 2 diabetes mellitus patients in Taiwan. A structured questionnaire was adopted from the theory of health belief model and modified specifically for this study as an instrument to survey 292 DM patients, of whom 51.03% were female, 75.68% were married, and 49.32% were aged 40 to 64 years old. The data were analyzed using t-tests, one-way ANOVA and regression. RESULTS: Perceived susceptibility was the most sensitive in the response to the various demographic factors, whereas perceived barrier was the least sensitive. The HBM explained 38.0% of BMP intake behavior. Perceived benefits (ß= 0.357) and perceived susceptibility (ß= 0.348) were the major predictors. Self-efficacy mediated the relationship between perceived benefits and BMP intake behavior, as well as increased the variance explained to 51.30%. CONCLUSION: The perceived benefits of taking BMP and perceived susceptibility to DM complications were the two major drivers acting on BMP intake behavior. The power of perceived benefits was mediated by self-efficacy in driving DM patients to take BMP regularly. Several ways of affecting perceived susceptibility and perceived benefits were suggested.

mcIRBP-19 of Bitter Melon Peptide Effectively Regulates Diabetes Mellitus (DM) Patients' Blood Sugar Levels.

This study was conducted to test the effectiveness of a particular bitter melon peptide (BMP), with a specific sequence of 19 amino acids (mcIRBP-19), in regulating diabetic patients' blood glucose. In order to test the product with the specially processed BMP, a total of 142 diabetic patients were solicited as study subjects, of which 64 were assigned to an experiment group and 78 to a control group. Biochemical data were compared with a paired t-test to verify the significance of changes over different time periods. The clinical results showed that BMP started to improve the subjects' glycated hemoglobin (HbA1c) levels at the end of the second month (T2), with mean values being significantly lowered from 7.8 ± 1.4% (T0) to 7.5 ± 1.4% (T2) (p = 0.004). The values reduced continuously, eventually reaching 7.4 ± 1.1% (p = 0.000) at the end of the experiment (T3). HbA1c levels for the control group were 7.5 ± 1.2% in T0 and 7.5 ± 1.1% (T3), and not significantly different (p = 0.852) over the same period. This study provides clinical evidence that helps to verify the effectiveness of the new BMP product in regulating diabetic patients' blood sugar levels.

Protein enrichment and digestion improvement of napiergrass and pangolagrass with solid-state fermentation.

BACKGROUND AND PURPOSE: Napiergrass (Pennisetum purpureum Schumacher) and pangolagrass (Digitaria decumbens Stent) are two major forage grasses for cow feeding. They possess high yields and high regeneration properties. Inoculation of cellulolytic microbes on herbage could enhance the protein content of herbage and promote digestibility in chickens. METHODS: Cellulolytic microbes were isolated from various sources and cultivated on napiergrass and pangolagrass with solid-state fermentation for protein enrichment and in vitro digestion improvement.The fermented napiergrass and pangolagrass were used as the main protein source in chicken diets to assess the feasibility for non-ruminants feed. RESULTS: After a 42-day fermentation period, napiergrass showed higher protein contents (13.4-13.9%) than those of pangolagrass(11.1-11.7%). The in vitro digestibility of pangolagrass increased from 5.29% to 20.4%, whereas that of napiergrass increased from 5.29% to 19.0%. The average feed conversion efficiencies of chickens were close to the traditional fodder using corn as the main ingredient. CONCLUSION: Inoculation of appropriate cellulolytic microbes to enrich protein content and improve in vitro digestibility of herbage with solid-state fermentation for chicken feed is the prospective technique for agriculture, animal husbandry, and substantial management.

Micronization increases vitamin E carrying and releasing abilities of insoluble fiber.

This study was to investigate the effects of micronization on vitamin-carrying capacity and slow-release ability of carambola (starfruit) insoluble fiber (IF) and cellulose using in vitro and in vivomodels. Upon micronization, carambola IF (8.1 microm) underwent structural changes to expose more functional groups in the fiber matrix and to exhibit higher oil-holding capacity ( approximately 20.4-fold). Micronized fibers in forms of fiber-vitamin composites, particularly the micronized carambola IF-vitamin composite, were capable of carrying vitamin E (alpha-tocopherol) up to 9.6-fold over their unmicronized forms and releasing nutrient gradually. Animal studies demonstrated that the adminstration of micronized carambola IF-vitamin composite could maintain the plasma vitamin E of rats at relatively higher levels (2.1-3.6-fold of the initial values) for at least 5 h. The results suggested that micronized fibers, particularly the micronized carambola IF, could be exploited as potential nutrient carriers in food applications and also be used to produce slow-release formulations.